Followers | 35 |
Posts | 6308 |
Boards Moderated | 0 |
Alias Born | 02/09/2015 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 14, 2015 12:26:22 PM
Speaker:K has been so well-tolerated that we cannot yet find a maximum dosing. In fact, we are now 10 times our original dosing, and it may go higher.
Audience: (Hushed tones, or even whispers.)I told you that it was well-tolerated. Now do you believe me? Just show me a better tolerated anti cancer compound than that already.
Other audience members: tones not hushed, rise to their feet: Go higher, go higher with the doses! More cohorts! Higher and more!!
Speaker: Our next agenda is to work to find ideal doses and intervals. This may take some time.
Audience, murmurs: Time- we've got some more of that don't we? Surely we do. Safety first. It's Phase 1.
Other audience members, again the rabble, shouting, in a reprise: Higher and more! Higher and more!
Speaker: Also, as expected, p21 levels have risen in the later cohorts. If you will look at slide 17 you will see...
Audience, murmurs: Wasn't that in the corporate update? At least now we can get some details- look, actual data. I think that's a graph! Look!
Speaker: we plan to initiate the Bologna trials with Cytarabine and Kevetrin
Audience, chanting: Bologna, Bologna, Bologna
Speaker: There has been stabilization of tumors in some patients.
Audience, subdued: OK OK, here we are at the appropriate venue. This is it! This is what we came for. C'mon, c'mon...
Speaker: You must remember these are very small patient samples, and we hope to make more data available later.
Audience, crestfallen, building toward sullen: Is that all there is? Is that all there is? Special K?
Speaker: We expect more trial data to become available as new dosing regimens are in place.
Audience, stumbling toward exits: what room is the xyz presentation in? Do you think Brilacidin has anti-tumor activity? Wasn't this all in the update?
I hope I am wrong.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM